Coherus BioSciences
333 Twin Dolphin Dr, #600
Redwood City
CA
94065
United States
Tel: 800-794-5434
Website: https://www.coherus.com/
About Coherus BioSciences
Coherus is focused on expanding patient access to important, cost-effective medicines and delivering significant savings to the U.S. healthcare system. Every member of the Coherus team is dedicated, motivated, and passionate about expanding patient access to lifesaving therapeutics. Our colleagues are experts in analytical and process sciences, deeply experienced in clinical development and regulatory affairs, and have proven commercial and marketing capabilities. Everyone at Coherus is committed to meeting the highest standards, inspiring our teammates, and achieving our goals.
Coherus was founded a decade ago to provide the highest quality biosimilar treatments to patients. We are proud to now be expanding our legacy—to build on our success with biosimilars and to focus our core strengths on immuno-oncology.
At Coherus, our employees are our most important asset. We have a dynamic and rewarding organizational culture that offers the opportunity to work with leading industry professionals who are dedicated to making a difference for patients. We are looking for individuals who see unlimited potential in themselves and are motivated by a continuous passion for breaking down barriers and expanding access to lifesaving therapeutics.
Coherus offers a competitive total rewards program comprised of various elements, including competitive base pay, short- and long-term incentives in the form of performance-based cash and equity, as well as health and wellness benefits that include
• Healthcare: Coherus pays 90% of premiums for medical, dental, and vision coverage for our
employees, their eligible spouses, dependents, and domestic partners.
• Health Savings and Flexible Spending Accounts
• Group Life, Disability, and Group Accident Insurance
• 401(k) with company match, and an Employee Stock Purchase Plan (ESPP)
• Paid Time Off (PTO)
• Health & Wellness programs, including a Health Club Reimbursement and an Employee Assistance Program
Health & Wellness programs, including a Health Club Reimbursement and an Employee Assistance Program
In addition to providing attractive rewards packages, we encourage and support our employees to find the right balance of work and personal time. Coherus offers a variety of activities, perks, and holidays that encourage employees to have a healthy outlook, spend time outside of work with friends and family, and foster a productive and collaborative work environment. Our culture is one in which we challenge and support all our team members to do their best work.
For more information about Coherus, please check out: https://www.coherus.com/about-coherus/
271 articles about Coherus BioSciences
-
Coherus BioSciences Announces New Employment Inducement Grants - February 03, 2023
2/3/2023
Coherus BioSciences, Inc., announced that effective February 1, 2023, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 22,500 shares of the common stock of the Company to three newly hired employees with a per share exercise price of $8.65, the closing trading price on the grant date.
-
Coherus Agrees to Acquire Exclusive U.S. Commercial Rights to Eylea® Biosimilar FYB203 from Klinge Biopharma
1/9/2023
Coherus BioSciences, Inc. (Coherus or Coherus BioSciences, Nasdaq: CHRS) announced today that it has executed a binding term sheet with Klinge Biopharma GmbH (Klinge Biopharma) for the exclusive commercialization rights to FYB203, a biosimilar candidate to Eylea® (aflibercept), in the United States.
-
Coherus BioSciences Management to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/4/2023
Coherus BioSciences, Inc., announced that senior management will present at the upcoming 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 8:15 a.m. Pacific Time.
-
Junshi Biosciences and Coherus Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
12/25/2022
Shanghai Junshi Biosciences Co., Ltd and Coherus BioSciences, Inc. announced that the companies have not received an action letter from the U.S. Food and Drug Administration regarding the Biologics License Application for toripalimab in combination with chemotherapy as treatment for recurrent or metastatic nasopharyngeal carcinoma by the Prescription Drug User Fee Action date of December 23, 2022.
-
Coherus and Junshi Biosciences Share Update on the FDA Review of the Biologics License Application (BLA) for Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
12/24/2022
Shanghai Junshi Biosciences Co., Ltd and Coherus BioSciences, Inc. announced that the companies have not received an action letter from the U.S. Food and Drug Administration regarding the Biologics License Application for toripalimab in combination with chemotherapy as treatment for recurrent or metastatic nasopharyngeal carcinoma by the Prescription Drug User Fee Action date of December 23, 2022.
-
Coherus BioSciences Reports Third Quarter 2022 Results and Provides Business Update
11/8/2022
Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today reported financial results for its fiscal third quarter ended September 30, 2022 and recent business highlights.
-
Coherus BioSciences to Report Third Quarter 2022 Financial Results on November 8th, 2022
11/1/2022
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that its third quarter 2022 financial results will be released after market close on Tuesday, November 8th, 2022.
-
Coherus and Junshi Biosciences Announce Publication of Positive Results from CHOICE-01, a Phase 3 Clinical Trial Evaluating Toripalimab
10/12/2022
Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) today announced the publication of toripalimab plus chemotherapy for patients with treatment-naïve advanced non-small cell lung cancer: a multi-center randomized phase 3 trial (CHOICE-01) in the Journal of Clinical Oncology.
-
Coherus to Launch CIMERLI™ (ranibizumab-eqrn) in the United States on October 3, 2022
9/19/2022
Coherus BioSciences, Inc. (Coherus or Coherus BioSciences, Nasdaq: CHRS) today announced the commercial availability, beginning October 3, 2022, of CIMERLI™ (ranibizumab-eqrn), a biosimilar product interchangeable with Lucentis® (ranibizumab injection) for all approved indications.
-
Coherus BioSciences Management to Present at H.C. Wainwright 24th Annual Global Investment Conference
9/12/2022
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today announced that senior management will participate at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14 at 10:00 am ET.
-
Coherus BioSciences Announces New Employment Inducement Grants - Aug 30, 2022
8/30/2022
Coherus BioSciences, Inc., announced that effective August 24, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 234,000 shares of the common stock of the Company to 22 newly hired employees with a per share exercise price of $12.90, the closing trading price on the grant date.
-
Coherus BioSciences Reports Second Quarter 2022 Results and Provides Business Update
8/4/2022
Coherus BioSciences, Inc., reported financial results for the quarter ended June 30, 2022 and recent business highlights.
-
FDA Approves Coherus’ CIMERLI™ (ranibizumab-eqrn) as the First and Only Interchangeable Biosimilar to Lucentis® for All Five Indications, with 12 Months of Interchangeability Exclusivity
8/2/2022
Coherus BioSciences, Inc. (Coherus or Coherus BioSciences, Nasdaq: CHRS) announced today that the U.S. Food and Drug Administration (FDA) has approved CIMERLI™ (ranibizumab-eqrn) as a biosimilar product interchangeable with Lucentis® (ranibizumab injection) for all five indications, meeting the FDA’s rigorous standards to the reference product, including safety, efficacy and quality.
-
Coherus BioSciences Announces New Employment Inducement Grants - Aug 02, 2022
8/2/2022
Coherus BioSciences, Inc., announced that effective August 1, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 250,000 shares of the common stock of the Company to two newly hired employees with a per share exercise price of $9.16, the closing trading price on the grant date.
-
The end of July is busy for the FDA, with Coherus, Sanofi, Acadia, Myovant and Pfizer having PDUFA dates filling the calendar. Here’s a look.
-
Coherus BioSciences to Report Second Quarter 2022 Financial Results on August 4th, 2022
7/28/2022
Coherus BioSciences, Inc., announced that its second quarter 2022 financial results will be released after market close on Thursday, August 4th, 2022.
-
A cancer drug co-developed by Coherus BioSciences and Junshi Biosciences, toripalimab, is getting another opportunity before the U.S. Food and Drug Administration.
-
Junshi Biosciences and Coherus Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
7/6/2022
Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (“Coherus”) announced today that the United States Food and Drug Administration ("FDA") has accepted for review the Biologics License Application (“BLA”) resubmission for toripalimab.
-
Coherus and Junshi Biosciences Announce FDA Acceptance of Resubmission of BLA for Toripalimab for the Treatment of Nasopharyngeal Carcinoma
7/6/2022
Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS) and Shanghai Junshi Biosciences Co., Ltd. (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) announced today that the United States Food and Drug Administration ("FDA") has accepted for review the Biologics License Application (“BLA”) resubmission for toripalimab.
-
Coherus BioSciences Announces New Employment Inducement Grants - June 22, 2022
6/22/2022
Coherus BioSciences, Inc., announced that effective June 16, 2022, the compensation committee of the Company’s board of directors granted options to purchase an aggregate of 409,000 shares of the common stock of the Company to 16 newly hired employees with a per share exercise price of $5.86, the closing trading price on the grant date.